| pubmed-article:2362269 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2362269 | lifeskim:mentions | umls-concept:C0001452 | lld:lifeskim |
| pubmed-article:2362269 | lifeskim:mentions | umls-concept:C1621296 | lld:lifeskim |
| pubmed-article:2362269 | lifeskim:mentions | umls-concept:C0456387 | lld:lifeskim |
| pubmed-article:2362269 | lifeskim:mentions | umls-concept:C0205250 | lld:lifeskim |
| pubmed-article:2362269 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:2362269 | pubmed:dateCreated | 1990-8-6 | lld:pubmed |
| pubmed-article:2362269 | pubmed:abstractText | The synthesis and receptor-binding profiles at adenosine receptor subtypes for a series of 2-(arylalkylamino)-adenosin-5'-uronamides is described. Halogenated 2-phenethylamino analogues such as 3e show greater than 200-fold selectivity for the A2 receptor subtype on the basis of rat brain receptor binding. The general structure-activity relationship of this series of compounds is discussed both in terms of potency at A2 receptors as well as receptor subtype selectivity. It is possible to introduce a hydrophilic carboxyalkyl substituent to this series such as in CGS 21680A (3h) and still retain good potency and selectivity for A2 receptors. In addition, functional data in a perfused working rat heart model shows that these compounds possess full agonist properties at A2 receptors with 3h having a greater than 1500-fold separation between A2 (coronary vasodilatory) and A1 (negative chronotropic) receptor mediated events. | lld:pubmed |
| pubmed-article:2362269 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2362269 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2362269 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2362269 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2362269 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2362269 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2362269 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2362269 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2362269 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:2362269 | pubmed:issn | 0022-2623 | lld:pubmed |
| pubmed-article:2362269 | pubmed:author | pubmed-author:WilliamsMM | lld:pubmed |
| pubmed-article:2362269 | pubmed:author | pubmed-author:EngR KRK | lld:pubmed |
| pubmed-article:2362269 | pubmed:author | pubmed-author:YokoyamaRR | lld:pubmed |
| pubmed-article:2362269 | pubmed:author | pubmed-author:VEISII | lld:pubmed |
| pubmed-article:2362269 | pubmed:author | pubmed-author:JarvisM FMF | lld:pubmed |
| pubmed-article:2362269 | pubmed:author | pubmed-author:HutchisonA... | lld:pubmed |
| pubmed-article:2362269 | pubmed:author | pubmed-author:StoneG AGA | lld:pubmed |
| pubmed-article:2362269 | pubmed:author | pubmed-author:GhaiG RGR | lld:pubmed |
| pubmed-article:2362269 | pubmed:author | pubmed-author:ZoganasH CHC | lld:pubmed |
| pubmed-article:2362269 | pubmed:author | pubmed-author:de JesusRR | lld:pubmed |
| pubmed-article:2362269 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2362269 | pubmed:volume | 33 | lld:pubmed |
| pubmed-article:2362269 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2362269 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2362269 | pubmed:pagination | 1919-24 | lld:pubmed |
| pubmed-article:2362269 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:2362269 | pubmed:meshHeading | pubmed-meshheading:2362269-... | lld:pubmed |
| pubmed-article:2362269 | pubmed:meshHeading | pubmed-meshheading:2362269-... | lld:pubmed |
| pubmed-article:2362269 | pubmed:meshHeading | pubmed-meshheading:2362269-... | lld:pubmed |
| pubmed-article:2362269 | pubmed:meshHeading | pubmed-meshheading:2362269-... | lld:pubmed |
| pubmed-article:2362269 | pubmed:meshHeading | pubmed-meshheading:2362269-... | lld:pubmed |
| pubmed-article:2362269 | pubmed:meshHeading | pubmed-meshheading:2362269-... | lld:pubmed |
| pubmed-article:2362269 | pubmed:meshHeading | pubmed-meshheading:2362269-... | lld:pubmed |
| pubmed-article:2362269 | pubmed:meshHeading | pubmed-meshheading:2362269-... | lld:pubmed |
| pubmed-article:2362269 | pubmed:meshHeading | pubmed-meshheading:2362269-... | lld:pubmed |
| pubmed-article:2362269 | pubmed:meshHeading | pubmed-meshheading:2362269-... | lld:pubmed |
| pubmed-article:2362269 | pubmed:meshHeading | pubmed-meshheading:2362269-... | lld:pubmed |
| pubmed-article:2362269 | pubmed:meshHeading | pubmed-meshheading:2362269-... | lld:pubmed |
| pubmed-article:2362269 | pubmed:meshHeading | pubmed-meshheading:2362269-... | lld:pubmed |
| pubmed-article:2362269 | pubmed:meshHeading | pubmed-meshheading:2362269-... | lld:pubmed |
| pubmed-article:2362269 | pubmed:meshHeading | pubmed-meshheading:2362269-... | lld:pubmed |
| pubmed-article:2362269 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2362269 | pubmed:articleTitle | 2-(Arylalkylamino)adenosin-5'-uronamides: a new class of highly selective adenosine A2 receptor ligands. | lld:pubmed |
| pubmed-article:2362269 | pubmed:affiliation | Research Department, CIBA-GEIGY Corporation, Summit, New Jersey 07901. | lld:pubmed |
| pubmed-article:2362269 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2362269 | pubmed:publicationType | In Vitro | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:2362269 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2362269 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2362269 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2362269 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2362269 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2362269 | lld:pubmed |
